RAPT

RAPT Therapeutics, Inc. (RAPT) | Rumor.io

RAPT Therapeutics

RAPT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)78%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RAPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Feb 2

GSK has launched a cash tender offer to acquire RAPT Therapeutics for an aggregate equity value of approximately $2.2bn.
The tender offer is scheduled to expire on March 2, 2026, with the deal expected to close in the first quarter of 2026 pending HSR clearance.
The acquisition is pending and has not yet closed, with no further details provided on the expected timeline or potential impact on the company.

Generated by AI

Sentiment

Of the messages about RAPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0% -100	88.94% +1.09
Bearish	—	100%	100% new	11.06% -1.09

Bullish· Feb 2

RAPT Therapeutics, Inc. has seen significant price gains, holding 17%+ on revenue facts, indicating visible execution.

Bearish· Dec 23

The company has a large float, making it difficult to short the stock.
The recent break above $1.60 has been a significant hurdle for the stock.
The stock has seen a reversal, and it's unclear whether weak hands are still holding on to the stock.

Generated by AI

Topics

Of the messages about RAPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	7.42%
Macro	—	—	0%	0%
Earnings	—	—	0%	0.08%
Controversies	—	—	0%	0.16%
Announcements	—	—	100%	84.12%
Analysts	—	—	0%	8.22%

Announcements· Jan 20

GSK has agreed to acquire RAPT Therapeutics in a $2.2 billion deal, with RAPT shareholders to receive $58 per share.
The acquisition includes RAPT's experimental anti-IgE antibody, ozureprubart, which is in phase IIb clinical development for prophylactic protection against food allergens.
The deal is expected to close in the first quarter of 2026, with GSK gaining global rights to ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong.

Technical Analysis· Dec 23

$RAPT is currently trending upward and has room to reach its potential high.
The stock has shown strength in holding above its VWAP and has some good volume, making it a promising opportunity.
A break above $1.82 is expected to send the stock running past $4, with a potential target of $2.40.

Generated by AI

Community

Of the messages about RAPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	60%	37.73%
Newcomers	—	0%	40%	62.27%

Regulars· Jan 20

The regulars are focused on the $2.2 billion buyout of RAPT Therapeutics by GSK, which is expected to bolster GSK's allergy pipeline.
The acquisition price of $58 per share has been announced, and the regulars are flagging the large market opportunity in food allergy, with estimates suggesting a $10 billion market size.
The regulars see positive readthrough to other companies in the food allergy space, with RAPT's acquisition being a testament to the market's potential, and Novartis' recent estimate of the market size supporting this view.

Newcomers· Feb 2

RAPT Therapeutics, Inc. is being acquired by GSK for an aggregate equity value of approximately $2.2 billion.
The acquisition is pending HSR clearance and is expected to close in the first quarter of 2026.
The tender offer, which is scheduled to expire on March 2, 2026, is being made by GSK to acquire all outstanding shares of RAPT Therapeutics.

Generated by AI

The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an adrenaline auto-injector (AAI) in the event of an allergic reaction. While antihistamines, corticosteroids, and bronchodilators are frequently used to manage associated symptoms, these agents do not treat anaphylaxis and should only be considered adjunctive therapies alongside epinephrine.

2mo agoYahoo Finance

Also Discussed

Investors talking about RAPT also mention

#	Name	Attention
1	Janux Therapeutics, Inc.JANX	0%0
2	ACCD - Accolade, Inc.	——
3	Nemaura Medical Inc.NMRD	0%new
4	KRTX - Karuna Therapeutics, Inc.	——
5	OCFT - OneConnect Financial Technology Co., Ltd.	——
6	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
7	ATHA - Athira Pharma, Inc.	——
8	LMP Automotive Holdings Inc.LMPX	0%0
9	ASLN - ASLAN Pharmaceuticals Limited	——
10	HARP - Harpoon Therapeutics, Inc.	——